Intellipharmaceutics Submits Investigational New Drug Application to the U.S. FDA for IPCI006 (oxycodone hydrochloride immediate release) Tablets Incorporating its Abuse Deterrent and Overdose Resistant Technology Nov 27, 2018
Intellipharmaceutics Reports Exclusive Supply Agreement for its Abuse-Deterrent Oxycodone ER Product Candidate and Four Generic Drug Products in the Philippines Nov 21, 2018
Intellipharmaceutics Regains Compliance with Nasdaq Minimum Shareholders' Equity Listing Requirements Oct 26, 2018
